Duexis

Zollinger-Ellison Syndrome, Curling Ulcer, Indigestion + 21 more

Treatment

4 FDA approvals

20 Active Studies for Duexis

What is Duexis

Famotidine

The Generic name of this drug

Treatment Summary

Famotidine is a medication used to reduce the production of stomach acid. It works by blocking the histamine-2 receptor, which helps to inhibit acid secretion in the stomach. It is commonly used to treat conditions such as gastric ulcers and GERD in both adults and children. It is more potent than similar medications, such as cimetidine and ranitidine, and can be taken as a pill or intravenously in a hospital setting.

Pepcid

is the brand name

image of different drug pills on a surface

Duexis Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Pepcid

Famotidine

1986

623

Approved as Treatment by the FDA

Famotidine, also called Pepcid, is approved by the FDA for 4 uses which include Heartburn and Heartburn .

Heartburn

Heartburn

prophylaxis of Heartburn

Heartburn

Effectiveness

How Duexis Affects Patients

Famotidine works by reducing acid in the stomach and decreasing the amount of acid and digestive enzymes produced. It's effects can be felt within one hour and last up to 12 hours. The more you take, the longer it will last and the more it will reduce your stomach acid.

How Duexis works in the body

Histamine is a hormone that tells stomach cells to produce acid. This happens when enterochromaffin-like cells release histamine, which is also triggered by the hormone gastrin. Histamine binds to receptors on the stomach cells, which increases the production of acid. In cases of ulcers or other conditions where too much acid is produced, famotidine steps in. Famotidine blocks the action of histamine on the stomach cells, reducing the amount of acid they produce.

When to interrupt dosage

The proposed measure of Duexis is contingent upon the diagnosed circumstance, such as Heartburn, Heartburn and Pathological Conditions, Anatomical. The measure of dosage is contingent upon the mode of administration (e.g. Tablet, film coated - Oral or Oral) exemplified in the table beneath.

Condition

Dosage

Administration

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Collagen Diseases

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Erosive Esophagitis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Obesity

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Zollinger-Ellison Syndrome

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Gastric ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Multiple Endocrine Neoplasia

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Critical Illness

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Spasm

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pathological Conditions, Anatomical

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Helicobacter Pylori Infection

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Osteoarthritis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Chronic Back Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

prophylaxis of Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Duodenal Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stomach Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Warnings

Duexis has one contraindication, so it ought not to be taken in combination with the conditions indicated in the following table.

Duexis Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Duexis.

Common Duexis Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Famotidine.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Famotidine.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Famotidine.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Famotidine.

Atazanavir

Major

Famotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.

Duexis Toxicity & Overdose Risk

The lowest dose of famotidine that has been found to be toxic in rats is 4049mg/kg, and 4686mg/kg in mice. The lowest toxic dose in humans is 4mg/kg, taken over a 7 day period. Symptoms of famotidine overdose are similar to those of recommended doses, and can be treated with supportive and symptomatic care. Removing unabsorbed drug from the gastrointestinal system and monitoring the patient is necessary. Hemodialysis can also be used to remove the drug from the bloodstream.

image of a doctor in a lab doing drug, clinical research

Duexis Novel Uses: Which Conditions Have a Clinical Trial Featuring Duexis?

45 active clinical trials are examining the potential of Duexis to ameliorate Collagen Diseases, Acid Indigestion and Muscle Spasms.

Condition

Clinical Trials

Trial Phases

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Chronic Back Pain

5 Actively Recruiting

Not Applicable

Collagen Diseases

0 Actively Recruiting

Gastric ulcer

0 Actively Recruiting

Critical Illness

0 Actively Recruiting

Gastritis

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Zollinger-Ellison Syndrome

0 Actively Recruiting

Curling Ulcer

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Multiple Endocrine Neoplasia

0 Actively Recruiting

Stress Ulcers

0 Actively Recruiting

Heartburn

0 Actively Recruiting

Spasm

0 Actively Recruiting

Erosive Esophagitis

2 Actively Recruiting

Phase 2, Phase 3

Obesity

0 Actively Recruiting

Pathological Conditions, Anatomical

3 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Osteoarthritis

0 Actively Recruiting

prophylaxis of Stress Ulcers

0 Actively Recruiting

Duexis Reviews: What are patients saying about Duexis?

5

Patient Review

8/6/2016

Duexis for Osteoarthritis and High Risk of Developing Gastric Ulcers

This treatment is really effective. I take it along with norco 10 and it does a great job at relieving my pain.

5

Patient Review

2/1/2019

Duexis for Joint Damage causing Pain and Loss of Function

The manufacturer's discount on this drug was incredible--60 pills for only $10. However, they withdrew the discount and now each pill costs $2,000. I've had to switch to taking ibuprofen and Pepcid ac daily, which is a real bummer. If you're on Medicare, beware that you won't be able to receive the discount either.

5

Patient Review

11/6/2016

Duexis for Osteoarthritis and High Risk of Developing Gastric Ulcers

I started taking this medication because I was having stomach problems with other pills. However, this pill helped my lower back pain.

5

Patient Review

12/22/2016

Duexis for Joint Damage causing Pain and Loss of Function

This drug has been a huge help for my plantar fasciitis.

5

Patient Review

3/27/2016

Duexis for Joint Damage causing Pain and Loss of Function

5

Patient Review

5/19/2017

Duexis for Rheumatoid Arthritis

Out of all the pills I've taken for my osteoarthritis, Duexis is the only one that's actually helped me. Not to mention, their co-pay card has been a lifesaver.

3.7

Patient Review

3/20/2019

Duexis for Gout

Kicks in 15-30 min and allows me to take it as needed. It manages any pain flare ups after a busy weekend doing yard work or house work. It works great and does not affect my GERD. My insurance did not want to pay for it so it came from a mail away pharmacy for $10. Cannot beat it. Great stuff.

3

Patient Review

7/15/2018

Duexis for Joint Damage causing Pain and Loss of Function

This medication is great for managing pain. I've used it for migraines, back pain, knee pain, and wrist pain with success. It usually kicks in within half an hour, which is awesome. Plus, it doesn't make me drowsy which is a huge plus.

2.7

Patient Review

7/29/2016

Duexis for Joint Damage causing Pain and Loss of Function

2.3

Patient Review

6/15/2017

Duexis for Joint Damage causing Pain and Loss of Function

Durexis helps with the pain from my surgery, but it only lasts for a few hours. I'm glad it exists, but I wish it were more effective.

1

Patient Review

5/21/2016

Duexis for Joint Damage causing Pain and Loss of Function

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about duexis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug DUEXIS used for?

"DUEXIS can be used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis, as well as decrease the risk of developing ulcers of the stomach and upper intestines in people taking ibuprofen for these conditions."

Answered by AI

Is DUEXIS good for inflammation?

"DUEXIS can provide OA and RA symptom relief, including pain and inflammation, when you would prefer to take a medication over having surgery. DUEXIS also has a lower risk of giving you stomach ulcers then ibuprofen taken alone."

Answered by AI

Is DUEXIS stronger than ibuprofen?

"DUEXIS® was also superior to ibuprofen in decreasing the risk for both gastric and duodenal ulcers."

Answered by AI

What is the difference between DUEXIS and ibuprofen?

"Are Duexis and Ibuprofen the Same Thing?

Duexis is a combination of ibuprofen and famotidine, and is used to treat signs and symptoms of rheumatoid arthritis. Because it contains famotidine, Duexis is also effective in reducing the risk of developing upper gastrointestinal ulcers. Ibuprofen is also used to treat primary dysmenorrhea."

Answered by AI

Clinical Trials for Duexis

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Have you considered Duexis clinical trials?

We made a collection of clinical trials featuring Duexis, we think they might fit your search criteria.
Go to Trials
Image of Public Health Research Center: Clinical Exercise Research Center in Columbia, United States.

Pistachio Snacking for Obesity

25 - 45
All Sexes
Columbia, SC

The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.

Recruiting
Has No Placebo

Public Health Research Center: Clinical Exercise Research Center

Katie R Hirsch, PhD

Have you considered Duexis clinical trials?

We made a collection of clinical trials featuring Duexis, we think they might fit your search criteria.
Go to Trials
Image of Villanova University in Villanova, United States.

BRAVE Intervention for Obesity Stigma

18 - 25
All Sexes
Villanova, PA

This randomized controlled trial will be a curriculum-embedded weight sensitivity training program. There will be two groups. The control group will receive the standard obesity lecture (SOL) and the intervention group will receive the BRAVE Intervention (BRAVE: Building Respect and Acceptance through Valuing Everybody); a Weight Bias Reduction (WBR) intervention. Both groups will have two simulation encounters with standardized patients who are living with obesity and the outcome will be to improve weight bias and increase weight sensitivity over one year. Participants will include second- and fourth-year nursing students. Two cohorts of nursing students will be recruited over two years during orientation for their NUR courses (n = 368); a combined total of 420 students are typically enrolled in these courses. Study participants will be randomized by 8-person simulation groups (clusters) to either the BRAVE intervention or SOL control group. They will then participate in the two simulation-based experiences and weight bias reduction education or standard obesity lecture, respectively, with a debriefing segment and educational components. To compare the efficacy of BRAVE groups to SOL groups in validated questionnaires will assess changing attitudes, beliefs, and clinical communication behaviors when comparing baseline to 3 months post-intervention, and one year after the intervention.

Waitlist Available
Behavior

Villanova University

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Local Restaurant Site in Bryan, United States.

Menu Labeling for Healthy Habits and Diet

18+
All Sexes
Bryan, TX

This study evaluates the impact of culturally tailored menu labeling interventions on psychosocial factors and ordering behavior among customers in two independently owned Hispanic restaurants in East-Central Texas. Participants will be exposed to one of three sequential menu conditions at each restaurant: (1) a standard menu without nutrition information, (2) a paper menu with bilingual nutrition labels, or (3) a digital menu app enhanced with Augmented Reality (AR) and Artificial Intelligence (AI) providing interactive nutrition guidance. The study will assess whether menu formats influence nutrition literacy, decision-making confidence, self-efficacy, attitudes, behavioral intentions, and actual ordering behavior. Data will be collected through surveys, purchase receipts, and app interaction logs.

Recruiting
Has No Placebo

Local Restaurant Site

Hyunjung Lee, PhD

Have you considered Duexis clinical trials?

We made a collection of clinical trials featuring Duexis, we think they might fit your search criteria.
Go to Trials